What the notice says
On 16 October 2026, the U.S. Centers for Disease Control and Prevention published a Level 2 (Practice Enhanced Precautions) travel health notice for yellow fever in Colombia, citing an increased number of reported cases. Level 2 is an advisory to take additional precautions — it is not a recommendation against travel.
Yellow fever is a viral illness spread by the bite of infected mosquitoes, including day-biting Aedes species in urban areas and forest-dwelling Haemagogus and Sabethes species in jungle and transitional zones. Most infections cause mild or non-specific symptoms, but a minority of cases progress to severe disease involving jaundice, bleeding, and organ failure. There is no antiviral cure; clinical care is supportive, which is why prevention carries the entire burden.
Public-information points for travelers
- Vaccination is the cornerstone of prevention. A single dose of yellow fever vaccine is generally considered to provide long-lasting protection for most recipients. The vaccine is administered only at authorized yellow fever vaccination centers, which also issue the International Certificate of Vaccination or Prophylaxis (ICVP, the "yellow card").
- Timing matters. Protection is generally regarded as established roughly 10 days after vaccination, so appointments should be arranged well in advance of departure — typically 4–6 weeks ahead.
- Entry requirements are separate from medical advice. Some countries require proof of yellow fever vaccination for arriving travelers, including those transiting from affected areas. Verify requirements for every leg of an itinerary with official sources.
- Mosquito-bite avoidance remains essential, including for vaccinated travelers, because the same mosquitoes transmit dengue, Zika, and chikungunya. Standard public-health guidance emphasizes EPA-registered repellents, covering clothing, and screened or air-conditioned accommodation.
- Seek prompt medical attention for fever, severe headache, muscle pain, or jaundice during travel or within weeks of return, and disclose the travel history.
Pharmacist's note: Yellow fever vaccine is a live attenuated product, which makes the pre-travel risk–benefit assessment genuinely individualized. Pregnancy, infancy and advanced age, thymus disorders or prior thymectomy, symptomatic HIV, haematologic malignancy, and immunosuppressive or biologic therapy are all factors that a qualified clinician must weigh — and in some cases a medical waiver letter is the appropriate route rather than vaccination. Bring a complete medication list to your travel consultation, including biologics and corticosteroids, since these are frequently omitted by patients. Also plan for repellent and insecticide supply volumes under airline liquid rules, and keep your yellow card with your passport rather than in checked baggage. This summary is general information, not personal medical advice; decisions about vaccination belong with your travel medicine provider.
Source: CDC Travelers' Health notice, 16 October 2026.